List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9430702/publications.pdf Version: 2024-02-01



FUL SECHI

#	Article	IF	CITATIONS
1	Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody. JAMA Neurology, 2019, 76, 301.	9.0	243
2	Positive Predictive Value of Myelin Oligodendrocyte Glycoprotein Autoantibody Testing. JAMA Neurology, 2021, 78, 741.	9.0	124
3	Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter study. Journal of Neurology, 2017, 264, 2420-2430.	3.6	120
4	Advances in clinical determinants and neurological manifestations of B vitamin deficiency in adults. Nutrition Reviews, 2016, 74, 281-300.	5.8	113
5	Anatomical variability of the lateral femoral cutaneous nerve: Findings from a surgical series. Clinical Anatomy, 2009, 22, 365-370.	2.7	96
6	Neurologic autoimmunity and immune checkpoint inhibitors. Neurology, 2020, 95, e2442-e2452.	1.1	94
7	Clinical spectrum of high-titre GAD65 antibodies. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 645-654.	1.9	84
8	Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): A Review of Clinical and MRI Features, Diagnosis, and Management. Frontiers in Neurology, 0, 13, .	2.4	84
9	Comparison of MRI Lesion Evolution in Different Central Nervous System Demyelinating Disorders. Neurology, 2021, 97, e1097-e1109.	1.1	77
10	Frequency and characteristics of MRI-negative myelitis associated with MOG autoantibodies. Multiple Sclerosis Journal, 2021, 27, 303-308.	3.0	64
11	Brainstem and cerebellar involvement in MOG-IgG-associated disorder versus aquaporin-4-IgG and MS. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 384-390.	1.9	55
12	Glial fibrillary acidic protein IgG related myelitis: characterisation and comparison with aquaporin-4-IgG myelitis. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 488-490.	1.9	54
13	Long-term Outcomes in Patients With Myelin Oligodendrocyte Glycoprotein Immunoglobulin G–Associated Disorder. JAMA Neurology, 2020, 77, 1575.	9.0	52
14	LGI1 antibody encephalitis: acute treatment comparisons and outcome. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 309-315.	1.9	48
15	Serum and CSF neurofilament light chain levels in antibody-mediated encephalitis. Journal of Neurology, 2019, 266, 1643-1648.	3.6	41
16	Neural Antibody Testing in Patients with Suspected Autoimmune Encephalitis. Clinical Chemistry, 2020, 66, 1496-1509.	3.2	41
17	Neurofilament light chain serum levels reflect disease severity in MOG-Ab associated disorders. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1293-1296.	1.9	40
18	Antibody-Mediated Autoimmune Diseases of the CNS: Challenges and Approaches to Diagnosis and Management. Frontiers in Neurology, 2021, 12, 673339.	2.4	40

#	Article	IF	CITATIONS
19	The frequency of longitudinally extensive transverse myelitis in MS: A population-based study. Multiple Sclerosis and Related Disorders, 2020, 37, 101487.	2.0	35
20	Aquaporin-4 and MOG autoantibody discovery in idiopathic transverse myelitis epidemiology. Neurology, 2019, 93, e414-e420.	1.1	26
21	CNS Demyelinating Attacks Requiring Ventilatory Support With Myelin Oligodendrocyte Glycoprotein or Aquaporin-4 Antibodies. Neurology, 2021, 97, e1351-e1358.	1.1	25
22	Risk of disease relapse following COVID-19 vaccination in patients with AQP4-IgC-positive NMOSD and MOGAD. Multiple Sclerosis and Related Disorders, 2022, 58, 103424.	2.0	25
23	Antibody response against HERV-W in patients with MOG-IgG associated disorders, multiple sclerosis and NMOSD. Journal of Neuroimmunology, 2020, 338, 577110.	2.3	23
24	Unilateral motor progression in MS. Neurology, 2019, 93, e628-e634.	1.1	22
25	Utility of MRI Enhancement Pattern in Myelopathies With Longitudinally Extensive T2 Lesions. Neurology: Clinical Practice, 2021, 11, e601-e611.	1.6	21
26	Variability of cerebrospinal fluid findings by attack phenotype in myelin oligodendrocyte glycoprotein-lgG-associated disorder. Multiple Sclerosis and Related Disorders, 2021, 47, 102638.	2.0	20
27	Diagnosis and Management of Autoimmune Dementia. Current Treatment Options in Neurology, 2019, 21, 11.	1.8	16
28	Serum and Cerebrospinal Fluid Biomarkers in Neuromyelitis Optica Spectrum Disorder and Myelin Oligodendrocyte Glycoprotein Associated Disease. Frontiers in Neurology, 2022, 13, 866824.	2.4	16
29	Late presentation of NMOSD as rapidly progressive leukoencephalopathy with atypical clinical and radiological findings. Multiple Sclerosis Journal, 2018, 24, 685-688.	3.0	15
30	Serum neurofilament light chain studies in neurological disorders, hints for interpretation. Journal of the Neurological Sciences, 2020, 416, 116986.	0.6	15
31	FLAIR-hyperintense Lesions in Anti-MOG-associated Encephalitis With Seizures (FLAMES): Is immunotherapy always needed to put out the fire?. Multiple Sclerosis and Related Disorders, 2020, 44, 102283.	2.0	15
32	Autoimmune encephalopathies presenting as dementia of subacute onset and rapid progression. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642199890.	3.5	15
33	HERV-K Modulates the Immune Response in ALS Patients. Microorganisms, 2021, 9, 1784.	3.6	15
34	Exploratory screening for Fabry's disease in young adults with cerebrovascular disorders in northern Sardinia. BMC Neurology, 2015, 15, 256.	1.8	14
35	Chronic Inflammatory Demyelinating Polyneuropathy after ChAdOx1 nCoV-19 Vaccination. Vaccines, 2021, 9, 1502.	4.4	13
36	Mycobacterium avium subspecies paratuberculosis and myelin basic protein specific epitopes are highly recognized by sera from patients with Neuromyelitis optica spectrum disorder. Journal of Neuroimmunology, 2018, 318, 97-102.	2.3	12

#	Article	IF	CITATIONS
37	Beyond Giant Cell Arteritis and Takayasu's Arteritis: Secondary Large Vessel Vasculitis and Vasculitis Mimickers. Current Rheumatology Reports, 2020, 22, 88.	4.7	12
38	Neurologic Complications of Immune Checkpoint Inhibitors in Thoracic Malignancies. Journal of Thoracic Oncology, 2021, 16, 381-394.	1.1	12
39	Ceftriaxone for Alexander's Disease: A Four-Year Follow-Up. JIMD Reports, 2012, 9, 67-71.	1.5	11
40	Teaching Neuro <i>Images</i> : Subacute encephalopathy in a young woman with <i>THTR2</i> gene mutation. Neurology, 2015, 85, e108-9.	1.1	11
41	Diagnostic value of aquaporin-4-IgG live cell based assay in neuromyelitis optica spectrum disorders. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021, 7, 205521732110526.	1.0	11
42	Antibody response against HERV-W env surface peptides differentiates multiple sclerosis and neuromyelitis optica spectrum disorder. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2017, 3, 205521731774242.	1.0	10
43	Safety profile of SARS-CoV-2 vaccination in patients with antibody-mediated CNS disorders. Multiple Sclerosis and Related Disorders, 2022, 63, 103827.	2.0	10
44	Serum Neurofilament to Magnetic Resonance Imaging Lesion Area Ratio Differentiates Spinal Cord Infarction From Acute Myelitis. Stroke, 2021, 52, 645-654.	2.0	9
45	Unfavorable outcome in highly relapsing MOGAD encephalitis. Journal of the Neurological Sciences, 2020, 418, 117088.	0.6	8
46	Evaluation and Management of Acute Myelopathy. Seminars in Neurology, 2021, 41, 511-529.	1.4	8
47	Paradoxical Effect of Levetiracetam in Newly Diagnosed Type II Focal Cortical Dysplasia. Clinical Neuropharmacology, 2016, 39, 265-268.	0.7	7
48	Critical spinal cord lesions associate with secondary progressive motor impairment in long-standing MS: A population-based case-control study. Multiple Sclerosis Journal, 2021, 27, 667-673.	3.0	7
49	Exposure to TNF inhibitors is rare at MOGAD presentation. Journal of the Neurological Sciences, 2022, 432, 120044.	0.6	7
50	Clinical Significance of Myelin Oligodendrocyte Glycoprotein Autoantibodies in Patients with Typical MS Lesions on MRI. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021, 7, 205521732110487.	1.0	5
51	Clinicopathologic features of folate-deficiency neuropathy. Neurology, 2015, 85, 1090-1091.	1.1	4
52	Plasma vitronectin is reduced in patients with myasthenia gravis: Diagnostic and pathophysiological potential. Journal of Circulating Biomarkers, 2019, 8, 184945441987591.	1.3	4
53	Hypertrophic olivary degeneration mimics relapse in neuromyelitis optica spectrum disorder. Neurology, 2019, 92, 343-344.	1.1	4
54	Area postrema syndrome in autoimmune GFAP astrocytopathy. Multiple Sclerosis Journal, 2020, 26, 255-256.	3.0	4

#	Article	IF	CITATIONS
55	Spinal arteriovenous fistula's often misdiagnosed as myelitis; can we stem the flow?. Journal of the Neurological Sciences, 2020, 413, 116868.	0.6	4
56	Onset of progressive motor impairment in patients with critical central nervous system demyelinating lesions. Multiple Sclerosis Journal, 2021, 27, 895-902.	3.0	4
57	Restless legs syndrome and cerebrovascular disease. Lancet Neurology, The, 2013, 12, 734.	10.2	3
58	Inflammatory activity following motor progression due to critical CNS demyelinating lesions. Multiple Sclerosis Journal, 2021, 27, 1037-1045.	3.0	3
59	Prolonged B-cell depletion after rituximab in AQP4-IgG-positive neuromyelitis optica spectrum disorder. Journal of Neuroimmunology, 2021, 358, 577666.	2.3	3
60	Teaching Video NeuroImage: Bilateral Hemifacial Spasm in Giant Cell Arteritis. Neurology, 0, , 10.1212/WNL.0000000000200837.	1.1	3
61	Neuralgic amyotrophy mimicking Vernet syndrome. Journal of the Neurological Sciences, 2016, 362, 230-231.	0.6	2
62	Applying the 2017 McDonald diagnostic criteria for multiple sclerosis. Lancet Neurology, The, 2018, 17, 498-499.	10.2	2
63	Neurochondrin immunoglobulin G – Associated myelopathy – Ataxia syndrome. Journal of the Neurological Sciences, 2021, , 120058.	0.6	2
64	Rasagiline Withdrawal Syndrome in Parkinson's Disease. Brain Sciences, 2022, 12, 219.	2.3	2
65	Cerebrospinal fluid evaluation in patients with progressive motor impairment due to critical central nervous system demyelinating lesions. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2022, 8, 205521732110521.	1.0	1
66	Longitudinally Extensive Spinal Cord Lesions Disclosing Occult Systemic Sarcoidosis. JAMA Neurology, 2016, 73, 600.	9.0	0
67	Diagnostic features of initial demyelinating events associated with serum MOG-IgG. Journal of Neuroimmunology, 2020, 344, 577260.	2.3	0